Neuronetics (NASDAQ:STIM) EVP Sells $21,446.70 in Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 16,005 shares of the stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $1.34, for a total transaction of $21,446.70. Following the completion of the transaction, the executive vice president directly owned 897,270 shares of the company’s stock, valued at approximately $1,202,341.80. The trade was a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Andrew Macan also recently made the following trade(s):

• On Thursday, February 26th, William Andrew Macan sold 3,427 shares of Neuronetics stock. The stock was sold at an average price of $1.35, for a total transaction of $4,626.45.
• On Thursday, February 12th, William Andrew Macan sold 14,120 shares of Neuronetics stock. The stock was sold at an average price of $1.65, for a total transaction of $23,298.00.
• On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The shares were sold at an average price of $1.55, for a total value of $5,401.75.

Neuronetics Trading Down 3.0%

NASDAQ STIM opened at $1.29 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. Neuronetics, Inc. has a twelve month low of $0.80 and a twelve month high of $4.85. The company has a market cap of $89.37 million, a price-to-earnings ratio of -2.19 and a beta of 0.87. The business’s fifty day moving average is $1.55 and its 200 day moving average is $1.96.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The business had revenue of $41.78 million for the quarter, compared to analyst estimates of $40.84 million. As a group, sell-side analysts expect that Neuronetics, Inc. will post -1.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Neuronetics

A number of institutional investors have recently made changes to their positions in STIM. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Neuronetics in the second quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new stake in Neuronetics during the 2nd quarter valued at approximately $37,000. Presidio Capital Management LLC acquired a new stake in Neuronetics during the 3rd quarter valued at approximately $32,000. Intrua Financial LLC bought a new position in Neuronetics during the 3rd quarter worth approximately $33,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Neuronetics in the 3rd quarter worth approximately $33,000. Institutional investors own 53.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on STIM. Canaccord Genuity Group dropped their price objective on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, March 19th. Wall Street Zen lowered shares of Neuronetics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Neuronetics presently has a consensus rating of “Hold” and an average price target of $3.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.